Stockwatch: 2010 earnings? it's all about 2011
This article was originally published in Scrip
The second full week of 2010 financial results added more weight to the emerging themes of the first week. While the impact of Pfizer's cuts to R&D and the probability of an increased Sanofi-Aventis bid for Genzyme continue to be debated, the rationale behind both these events featured subliminally in this week's results.